Cancer risk from inorganics.
Inorganic metals and minerals for which there is evidence of carcinogenicity are identified. The risk of cancer from contact with them in the work place, the general environment, and under conditions of clinical (medical) exposure is discussed. The evidence indicates that minerals and metals most often influence cancer development through their action as cocarcinogens. The relationship between the physical form of mineral fibers, smoking and carcinogenic risk is emphasized. Metals are categorized as established (As, Be, Cr, Ni), suspected (Cd, Pb) and possible carcinogens (Table 6), based on the existing in vitro, animal experimental and human epidemiological data. Cancer risk and possible modes of action of elements in each class are discussed. Views on mechanisms that may be responsible for the carcinogenicity of metals are updated and analysed. Some specific examples of cancer risks associated with the clinical use of potentially carcinogenic metals and from radioactive pharmaceuticals used in therapy and diagnosis are presented. Questions are raised as to the effectiveness of conventional dosimetry in accurately measuring risk from radiopharmaceuticals.
D000818:Animals; D001682:Biological Availability; D002869:Chromosome Aberrations; D004247:DNA / Q000378:metabolism; D004249:DNA Damage; D006801:Humans; D007633:Keratins / Q000378:metabolism; D008094:Lithium / Q000633:toxicity; D008670:Metals / Q000378:metabolism / Q000633:toxicity*; D008903:Minerals / Q000633:toxicity; D009154:Mutation; D009369:Neoplasms / Q000139:chemically induced*; D010984:Platinum / Q000633:toxicity; D011868:Radioisotopes / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012306:Risk
D008670:Metals; D008903:Minerals; D011868:Radioisotopes; D010984:Platinum; D007633:Keratins; D004247:DNA; D008094:Lithium